Tekmira Pharmaceuticals Corp  

(Public, NASDAQ:TKMR)   Watch this stock  
Find more results for TKMR
-0.24 (-1.73%)
After Hours: 13.70 +0.05 (0.36%)
May 22, 4:10PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.45 - 14.01
52 week 8.86 - 29.93
Open 13.79
Vol / Avg. 685,833.00/680,370.00
Mkt cap 747.70M
P/E     -
Div/yield     -
EPS -1.71
Shares 54.22M
Beta 0.35
Inst. own 66%
Aug 11, 2015
Q2 2015 Tekmira Pharmaceuticals Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 2, 2015
Tekmira Pharmaceuticals Corp at Jefferies Global Healthcare Conference - 3:30PM EDT - Add to calendar
May 7, 2015
Tekmira Pharmaceuticals Corp at Deutsche Bank Health Care Conference
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Call - Webcast
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Release
Mar 12, 2015
Q4 2014 Tekmira Pharmaceuticals Corp Earnings Call - Webcast
Mar 12, 2015
Q4 2014 Tekmira Pharmaceuticals Corp Earnings Release
Mar 11, 2015
Tekmira Pharmaceuticals Corp at Barclays Healthcare Conference - Webcast
Mar 3, 2015
Tekmira Pharmaceuticals Corp Extraordinary Shareholders Meeting
Feb 24, 2015
Tekmira Pharmaceuticals Corp at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -


100-8900 Glenlyon Pky
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Its product candidates include TKM-HBV, TKM-PLK1, TKM-Ebola and TKM-Marburg. TKM-HBV is an RNAi therapeutic for the treatment of Hepatitis B infection. The Company’s lead oncology product candidate, TKM -PLK1 is an oncology product platform that targets polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. TKM-ALDH2 is an application of RNAi for alcohol use disorder with a target patient population who have moderate to severe alcohol use disorder. TKM-Ebola is an anti-Ebola viral therapeutic being developed under a contract with the United States Department of Defense Joint Project Manager Medical Countermeasure Systems. TKM-Marburg is used to treat hemorrhagic fever viral infections.

Officers and directors

Vivek Ramaswamy Chairman of the Board
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 57
Bio & Compensation  - Reuters
Adam D. Cutler Senior Vice President - Corporate Affairs
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 59
Bio & Compensation  - Reuters
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
Bio & Compensation  - Reuters
Bruce Dorsey Vice President - Chemistry
Bio & Compensation  - Reuters
Rene Cornelis Rijnbrand Vice President - Biology
Bio & Compensation  - Reuters
R. Hector MacKay-Dunn Q.C. Corporate Secretary
Age: 62
Bio & Compensation  - Reuters